文献速递糖尿病肥胖与代谢综合征

2型糖尿病患者依折麦布联合治疗与高强度他汀单药治疗疗效比较

Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

本研究利用韩国国民健康保险索赔数据库,纳入≥20岁2型糖尿病合并血脂异常患者,经倾向评分匹配后比较低或中等强度他汀联合依折麦布与高强度他汀单药治疗。结果显示,中等强度他汀联合依折麦布较低密度脂蛋白胆固醇(LDL-C)和复合结局发生率均低于高强度他汀单药治疗(风险比0.85,95%可信区间0.74-0.98),而低强度他汀联合依折麦布与高强度他汀单药治疗无显著差异。

要点

  • 中等强度他汀联合依折麦布组LDL-C为74±37.9 mg/dL,低于高强度他汀单药组的80.8±38.8 mg/dL(P<0.001)。
  • 中等强度他汀联合依折麦布组复合结局(心肌梗死、卒中、全因死亡)风险比为0.85(95%可信区间0.74-0.98),低于高强度他汀单药组。
  • 低强度他汀联合依折麦布与高强度他汀单药治疗的LDL-C水平和复合结局无显著差异。

核心结论

  • 在2型糖尿病患者中,中等强度他汀联合依折麦布比高强度他汀单药治疗具有更强的LDL-C降低效果和更好的复合结局一级预防效果。

研究设计与样本

  • 本研究基于韩国国民健康保险索赔数据库,纳入年龄≥20岁的2型糖尿病合并血脂异常患者。
  • 研究经倾向评分匹配分析,比较低或中等强度他汀联合依折麦布与高强度他汀单药治疗。
  • 分析结局为心肌梗死、卒中、全因死亡的复合结局及各组分发生率。

主要发现

  • 中等强度他汀联合依折麦布组LDL-C为74±37.9 mg/dL,高强度他汀单药组为80.8±38.8 mg/dL(P<0.001)。
  • 中等强度他汀联合依折麦布组复合结局风险比为0.85(95%可信区间0.74-0.98),低于高强度他汀单药组。
  • 低强度他汀联合依折麦布与高强度他汀单药治疗在LDL-C水平和复合结局上无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Low-density lipoprotein cholesterol (LDL-C)-lowering therapy is considerably important in preventing cardiovascular disease (CVD) among patients with diabetes. Studies comparing CVD, stroke, and mortality outcomes of low- or moderate-intensity statins with ezetimibe combination therapy and high-intensity statin monotherapy in patients with diabetes remain lacking. OBJECTIVE: This study compared the primary prevention effect of myocardial infarction (MI), stroke, and all-cause death between combination therapy of low- or moderate-intensity statins and ezetimibe and high-intensity statin monotherapy in patients with diabetes using the Korean National Health Insurance claims database. METHODS: Patients aged ≥20 years with type 2 diabetes and dyslipidemia were enrolled. The combination therapy of low- or moderate-intensity statin and ezetimibe was compared with high-intensity statin monotherapy after a propensity score-matched analysis. The incidence of composite outcomes consisting of MI, stroke, and all-cause death and each component were analyzed. RESULTS: In moderate-intensity statin therapy with ezetimibe combination therapy, LDL-C (74 ± 37.9 mg/dL vs 80.8 ± 38.8 mg/dL, P < .001) and the incidence of composite outcomes were lower (hazard ratio 0.85, 95% CI 0.74-0.98) than those in high-intensity statin monotherapy. Meanwhile, no significant difference was observed in the LDL-C levels and composite outcomes between low-intensity statins with ezetimibe combination therapy and high-intensity statin monotherapy. CONCLUSION: Adding ezetimibe to a moderate-intensity statin in patients with type 2 diabetes has a greater LDL-C-lowering effect and greater primary prevention of composite outcomes than that of high-intensity statin monotherapy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Park SY, Jun JE, Jeong IK, et al. Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes. J Clin Endocrinol Metab. 2024. PMID: 38175670. doi:10.1210/clinem/dgad714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。